Type to search

Quell Therapeutics Raises $156 Million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | Pharmtech Focus
Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy | Pharmtech Focus
Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer | Pharmtech Focus